Ultragenyx Faces Securities Fraud Class Action Over Failed Drug Trials

Reuters

Feb 10

Ultragenyx Faces Securities Fraud Class Action Over Failed Drug Trials

A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc., a biopharmaceutical company specializing in treatments for rare diseases, on behalf of investors who purchased the company's common stock between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx misled investors about the effectiveness of its ORBIT and COSMIC studies, which tested setrusumab as a treatment for Osteogenesis Imperfecta, by concealing that neither study significantly reduced clinical fracture rates compared to control groups. Following the disclosure of this information, Ultragenyx's share price dropped by more than 42%, from $34.19 on December 26, 2025, to $19.72 on December 29, 2025. Investors who acquired Ultragenyx securities during the class period have until April 6, 2026, to seek appointment as lead plaintiff in the case.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 283209) on February 10, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610629020"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610629020\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610629020?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 23:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610629020","market":"nz","top_or_hot":-1,"title":"Ultragenyx Faces Securities Fraud Class Action Over Failed Drug Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ultragenyx Faces Securities Fraud Class Action Over Failed Drug Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A class action lawsuit has been filed against <a href=\"https://laohu8.com/S/RARE\">Ultragenyx Pharmaceutical Inc</a>., a biopharmaceutical company specializing in treatments for rare diseases, on behalf of investors who purchased the company's common stock between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx misled investors about the effectiveness of its ORBIT and COSMIC studies, which tested setrusumab as a treatment for Osteogenesis Imperfecta, by concealing that neither study significantly reduced clinical fracture rates compared to control groups. Following the disclosure of this information, Ultragenyx's share price dropped by more than 42%, from $34.19 on December 26, 2025, to $19.72 on December 29, 2025. Investors who acquired Ultragenyx securities during the class period have until April 6, 2026, to seek appointment as lead plaintiff in the case.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 283209) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ultragenyx Faces Securities Fraud Class Action Over Failed Drug Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUltragenyx Faces Securities Fraud Class Action Over Failed Drug Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-10 23:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ultragenyx Faces Securities Fraud Class Action Over Failed Drug Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A class action lawsuit has been filed against <a href=\"https://laohu8.com/S/RARE\">Ultragenyx Pharmaceutical Inc</a>., a biopharmaceutical company specializing in treatments for rare diseases, on behalf of investors who purchased the company's common stock between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx misled investors about the effectiveness of its ORBIT and COSMIC studies, which tested setrusumab as a treatment for Osteogenesis Imperfecta, by concealing that neither study significantly reduced clinical fracture rates compared to control groups. Following the disclosure of this information, Ultragenyx's share price dropped by more than 42%, from $34.19 on December 26, 2025, to $19.72 on December 29, 2025. Investors who acquired Ultragenyx securities during the class period have until April 6, 2026, to seek appointment as lead plaintiff in the case.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 283209) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RARE","symbol_name":"Ultragenyx Pharmaceutical Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL7gV5nt:1","article_id":"2610629020","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610629020","pubTimestamp":1770736036,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc., a biopharmaceutical company specializing in treatments for rare diseases, on behalf of investors who purchased the company's common stock between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx misled investors about the effectiveness of its ORBIT and COSMIC studies, which tested setrusumab as a treatment for Osteogenesis Imperfecta, by concealing that neither study significantly reduced clinical fracture rates compared to control groups. Following the disclosure of this information, Ultragenyx's share price dropped by more than 42%, from $34.19 on December 26, 2025, to $19.72 on December 29, 2025. Investors who acquired Ultragenyx securities during the class period have until April 6, 2026, to seek appointment as lead plaintiff in the case.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RARE":"Ultragenyx Pharmaceutical Inc","BK4139":"生物科技"},"translate_title":"Ultragenyx因药物试验失败面临证券欺诈集体诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RARE":0.9},"content_text":"Ultragenyx Faces Securities Fraud Class Action Over Failed Drug Trials\n    \n\n        A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc., a biopharmaceutical company specializing in treatments for rare diseases, on behalf of investors who purchased the company's common stock between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx misled investors about the effectiveness of its ORBIT and COSMIC studies, which tested setrusumab as a treatment for Osteogenesis Imperfecta, by concealing that neither study significantly reduced clinical fracture rates compared to control groups. Following the disclosure of this information, Ultragenyx's share price dropped by more than 42%, from $34.19 on December 26, 2025, to $19.72 on December 29, 2025. Investors who acquired Ultragenyx securities during the class period have until April 6, 2026, to seek appointment as lead plaintiff in the case.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 283209) on February 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}